ArticleCureus2026
E-Cadherin Immunohistochemical Expression in Gastrointestinal Adenocarcinomas and Its Association With Histological and Prognostic Parameters.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundE-cadherin (CDH1) is a critical cell adhesion molecule that maintains epithelial tissue integrity. Its loss or dysfunction is a hallmark of the epithelial-mesenchymal transition (EMT) and is mostly implicated in gastrointestinal adenocarcinomas, their invasion, and metastasis.
objectivesThis study aims to evaluate the patterns of E-cadherin immunohistochemical expression in gastrointestinal (GI) adenocarcinomas using a semi-quantitative scoring system and to correlate these patterns with the histological and prognostic factors of tumors.
methodsThis prospective and retrospective observational study included 50 patients diagnosed with GI adenocarcinoma (stomach, colon, and rectum) at a tertiary care center. Immunohistochemistry (IHC) for E-cadherin was performed on formalin-fixed paraffin-embedded tissue, and the expression of E-cadherin was evaluated using the Jawhari et al. scoring system. Statistical associations between expression patterns and clinicopathological variables were analyzed using the chi-square test, with a p-value < 0.05 considered significant.
resultsThe study population (N=50) comprised 21 gastric (42%), 10 colonic (20%), and 19 rectal adenocarcinomas (38%). Reduced or absent staining of E-cadherin (score 0 - 1) was seen in 19 (38%) of GI adenocarcinomas, and 14 (28%) tumors showed completely preserved E-cadherin expression (score 3). Well-differentiated tumors showed preserved E-cadherin expression (scores 2-3 in all cases), whereas poorly differentiated tumors predominantly showed reduced or complete loss of expression (p=0.001). Adenocarcinoma NOS and intestinal-type tumors largely retained E-cadherin, while signet ring cell, mucinous, and infiltrating types frequently demonstrated markedly decreased expression (p=0.001). No statistically significant association was observed between tumor site and E-cadherin expression. Reduced or absent E-cadherin expression was significantly associated with advanced tumor stage (p=0.002), higher nodal stage (p=0.018), and perineural invasion (p=0.008).
conclusionE-cadherin dysregulation is strongly associated with histological tumor grade, adenocarcinoma type, tumor stage, nodal metastasis, and perineural invasion in GI adenocarcinomas. The significant loss of expression in poorly differentiated and infiltrating tumor types supports its role as an invasion suppressor. Loss of E-cadherin expression in advanced tumor stages, higher nodal metastasis, and perineural invasion elucidate the role of E-cadherin as a useful prognostic immunohistochemical marker in gastrointestinal adenocarcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.